logo
logo
logo
logo
  • News
  • Approach
  • ESG
  • Portfolio
  • Team
  • Tech Investments
  • Contact

Month: January 2021

ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury


ONWARD announced the publication of a study in the journal, Nature, which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI).


by eazee-designstudio

ONWARD Completes $32 Million Financing Round

ONWARD, announced the Company has successfully completed a $32M financing. The round was led by Invest-NL, the Dutch impact investor, and Olympic Investments, the private investment arm of the Onassis Foundation. Several additional new investors and all of ONWARD’s existing investors also participated in the financing, including leading medical technology investors LSP, INKEF Capital, Gimv, and Wellington Partners.


by eazee-designstudio

ONWARD Announces First Patient Enrolled in the Up-LIFT Pivotal Trial Assessing Safety and Effectiveness of ARC Therapy for Spinal Cord Injury


ONWARD, formerly known as GTX Medical, today announced the first patient has been enrolled in a pivotal trial evaluating the Company’s ARC TherapyTM.


by eazee-designstudio

Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch

Quanta announced that it has received 510(k) clearance from the
US Food and Drug Administration (“FDA”) to market its small and simple, high performance hemodialysis system SC+.


by eazee-designstudio

PerkinElmer to Acquire Oxford Immunotec Global PLC


PerkinElmer and Oxford Immunotec Global PLC are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec.


by eazee-designstudio

CARISMA Therapeutics Appoints Richard Morris as Chief Financial Officer

CARISMA Therapeutics, announced that Richard Morris has been appointed Chief Financial Officer (CFO).


by eazee-designstudio

CARISMA Therapeutics Completes Series B Funding for $47 Million to Advance Development of Novel CAR-Macrophage Immunotherapies

CARISMA Therapeutics announced today that it has completed its
Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA’s total capital
raised to nearly $109 million.


by eazee-designstudio

Recent Posts

  • Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
  • ImCheck Appoints Thomas Civik as Independent Chairman of the Board
  • Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
  • Carisma Therapeutics Closes Merger with Sesen Bio
  • Confo Therapeutics Announces Global Licensing Agreement With Lilly For Peripheral Pain Candidate, CFTX-1554

Archives

  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
  • September 2021
  • August 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
  • June 2018
  • March 2018
  • February 2018
  • January 2018
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • June 2016
  • May 2016

Categories

  • Wellington Partners
  • Portfolio News

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

© 2022 Wellington Partners. All rights reserved  |  Imprint  |  Privacy Policy | SFDR Disclosures | PRIIPS

Privacy Preference Center

Privacy Preferences